Fig. 6From: Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalenceImpact of duration of protection in HIV+ subpopulation: (a) overall population, (b) HIV+ subpopulation. BC, base case; CC, cervical cancer; GDP, gross domestic product; HIV, human immunodeficiency virus; HIV+, HIV-positive; HIV-, HIV-negative; ICER, incremental cost-effectiveness ratio; ZAR, South African RandBack to article page